BIG
MLTX icon

Brooklyn Investment Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Brooklyn Investment Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,920
Closed -$204K – 1967
2025
Q4 		$204K Buy
+14,920
New +$176K 0.01% 1356
2025
Q3 		– Sell
-110
Closed -$5.19K – 1903
2025
Q2 		$5.19K Buy
+110
New +$4.48K ﹤0.01% 2452
2025
Q1 		– Sell
-78
Closed -$4.22K – 2837
2024
Q4 		$4.22K Buy
+78
New +$3.98K ﹤0.01% 1273

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Brooklyn Investment Group's MLTX Position: Q1 2026 in Review

Brooklyn Investment Group sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2026, closing a stake of 14,920 shares — an estimated $204K sold.

Brooklyn Investment Group first reported a position in MLTX in Q4 2024 and held it in 3 quarters. The position peaked at $204K in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Brooklyn Investment Group reported no remaining MoonLake Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Brooklyn Investment Group sold 14,920 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $204K.
  • Brooklyn Investment Group first reported a position in MoonLake Immunotherapeutics in Q4 2024 and held it in 3 quarters.
  • Brooklyn Investment Group's MoonLake Immunotherapeutics position peaked at $204K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.